Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4

Comparative Hepatology

Volumn 9, Issue , 2010, Pages

  Zekri, Abdel Rahman N ^a   El Din, Hanaa M A ^a   Bahnassy, Abeer A ^b   Zayed, Naglaa A ^c   Mohamed, Waleed S ^a   El Masry, Suzan H ^d   Gouda, Sayed K ^d   Esmat, Gamal ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; FAS ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 8; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE;

EID: 76749165309     PISSN: None     EISSN: 14765926     Source Type: Journal    
DOI: 10.1186/1476-5926-9-1     Document Type: Article

References (66)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750. 10.1056/NEJM199903113401001, 10072408.
3. Shibuya K, Yano E. Regression analysis of trends in mortality from hepatocellular carcinoma in Japan, 1972-2001. Int J Epidemiol 2005, 34:397-402. 10.1093/ije/dyh358, 15561746.
4. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M, Bru C, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989, 2:1004-1006. 10.1016/S0140-6736(89)91015-5, 2572739.
5. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, Dioguardi N, Houghton M. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989, 2:1006-1008. 10.1016/S0140-6736(89)91016-7, 2572740.
6. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567. 10.1016/S1473-3099(05)70216-4, 16122679.
7. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355:887-891. 10.1016/S0140-6736(99)06527-7, 10752705.
8. Nafeh MA, Medhat A, Shehata M, Mikhail NN, Swifee Y, Abdel-Hamid M, Watts S, Fix AD, Strickland GT, Anwar W, Sallam I. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg 2000, 63:236-241.
9. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Thomas D, Fix AD, Strickland GT, Anwar W, Sallam I. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000, 32:111-115. 10.1053/jhep.2000.8438, 10869297.
10. El-Sadawy M, Ragab H, el-Toukhy H, el-Mor A, Mangoud AM, Eissa MH, Afefy AF, el-Shorbagy E, Ibrahem IA, Mahrous S, Abdel-Monem A, Sabee EI, Ismail A, Morsy TA, Etewa S, Nor Edin E, Mostafa Y, Abouel-Magd Y, Hassan MI, Lakouz K, Abdel-Aziz K, el-Hady G, Saber M. Hepatitis C virus infection at Sharkia Governorate, Egypt: seroprevalence and associated risk factors. J Egypt Soc Parasitol 2004, 34(Suppl 1):367-384.
11. Deuffic-Burban S, Mohamed MK, Larouze B, arrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol 2006, 44:455-461. 10.1016/j.jhep.2005.08.008, 16310281.
12. Ahn J, Chung KS, Kim DU, Won M, Kim L, Kim KS, Nam M, Choi SJ, Kim HC, Yoon M, Chae SK, Hoe KL. Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus. J Biochem Mol Biol 2004, 37:741-748.
13. Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu-Shady MA. Cytokine profile in Egyptian HCV genotype-4 in relation to liver disease progression. World Journal of Gastroenterology 2005, 11:6624-6630.
14. Zekri AR, Haleem HA, Esmat GE, Bahnassy AA, El-Din HM, Hafez MM, Sharaby AF, Sharaf H, Zakaria MS. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. J Viral Hepatol 2007, 14:468-477.
15. Chen J, Zheng XH, Tang XP. [A comparative study of serum sFas in patients with hepatocellular cancer and chronic hepatitis]. Hunan Yi Ke Da Xue Xue Bao 2001, 26:173-174.
16. Sacco R, Leuci D, Tortorella C, Fiore G, Marinosci F, Schiraldi O, Antonaci S. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine 2000, 12:811-814. 10.1006/cyto.1999.0650, 10843770.
17. Izzo F, Cremona F, Delrio P, Leonardi E, Castello G, Pignata S, Daniele B, Curley SA. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein. Ann Surg Oncol 1999, 6:178-185. 10.1007/s10434-999-0178-1, 10082044.
18. Chuang E, Del Vecchio A, Smolinski S, Song XY, Sarisky RT. Biomedicines to reduce inflammation but not viral load in chronic HCV: what's the sense?. Trends Biotechnol 2004, 22:517-523. 10.1016/j.tibtech.2004.08.011, 15450745.
19. Koulentaki M, Notas G, Petinaki E, Valatas V, Mouzas IA, Castanas E, Kouroumalis EA. Nitric oxide and pro-inflammatory cytokines in acute hepatitis B. Eur J Intern Med 2004, 15:35-38. 10.1016/j.ejim.2003.11.004, 15066646.
20. Choi J, Ou JHJ. Mechanisms of liver injury: III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006, 290:G847-G851. 10.1152/ajpgi.00522.2005, 16603728.
21. Schwabe RF, Brenner DA. Mechanisms of liver injury: I.TNF-a- induced liver injury: role of IKK, JNK, ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006, 290:G583-G589. 10.1152/ajpgi.00422.2005, 16537970.
22. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol 2005, 11:3260-3263.
23. Odeh M, Sabo E, Srugo I, Oliven A. Relationship between tumor necrosis factor-a and ammonia in patients with hepatic encephalopathy due to chronic liver failure. Ann Med 2005, 37:603-612. 10.1080/07853890500317414, 16338762.
24. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, Petrarca C, Pizzigallo E, Conti P, Vecchiet J. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 2006, 36:144-150.
25. Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, George J. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007, 46:66-73. 10.1002/hep.21703, 17596870.
26. Elsammak M, Refai W, Elsawaf A, Abdel-Fattah I, Abd Elatti E, Ghazal A. Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin 2005, 21:527-534. 10.1185/030079905X38141, 15899101.
27. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Nooman A, Massoud M, Koziel MJ, Afdhal NH. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006, 43:771-779. 10.1002/hep.21117, 16557547.
28. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY. Activation of tumor necrosis factor a system in chronic hepatitis C virus infection. Dig Dis Sci 1997, 42:2487-2494. 10.1023/A:1018804426724, 9440625.
29. Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, Hornik V, Levo Y, Maini RN, Feldmann M, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993, 36:1111-1120. 10.1002/art.1780360812, 8393677.
30. Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, Singer MV, Rossol S. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998, 111:269-277. 10.1046/j.1365-2249.1998.00469.x, 9486392, 1904907.
31. Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, Bach JF, Bréchot C, Zavala F. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999, 30:185-191. 10.1016/S0168-8278(99)80060-9, 10068094.
32. Kaplanski G, Marin V, Maisonobe T, Sbai A, Farnarier C, Ghillani P, Thirion X, Durand JM, Harlé JR, Bongrand P, Piette JC, Cacoub P. Increased soluble p55 and p75 tumour necrosis factor-a receptors in patients with hepatitis C-associated mixed cryoglobulinaemia. Clin Exp Immunol 2002, 127:123-130. 10.1046/j.1365-2249.2002.01728.x, 1906273, 11882042.
33. Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K, Aikou T. Interleukin 8 in Human Hepatocellular Carcinoma Correlates With Cancer Cell Invasion of Vessels But Not With Tumor Angiogenesis. Ann Surg Oncol 2005, 12:800-807. 10.1245/ASO.2005.07.015, 16132378.
34. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007, 4:424-432. 10.1038/ncponc0844, 17597707.
35. Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992, 103:264-274.
36. Jacobson-Brown P, Neuman M. Th1/Th2 responses and the role of cytokines. Clin Biochem 2001, 34:167-171. 10.1016/S0009-9120(01)00210-7, 11408013.
37. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006, 80:1197-1213. 10.1189/jlb.0506297, 16946019.
38. Aref S, Menessy A. Correlation of soluble IL-2R and tumor necrosis factor α receptor (TNF-αR) levels with severity of chronic hepatitis C liver injury. The Egypt J Hematol 1997, 22:327-340.
39. Quentmeier H, Dirks WG, Fleckenstein D, Zaborski M, Drexler HG. Tumor necrosis factor-α induced proliferation requires synthesis of granulocyte macrophage colony-stimulating factor. Exp Hematol 2000, 28:1008-10015. 10.1016/S0301-472X(00)00516-6, 11008013.
40. Sugiyama M, Kanno T, Ohkubo A, Muto Y, Murata K, Ueno Y. The clinical usefulness of the molar ratio of branched-chain amino acids to tyrosine (BTR) in discriminating stage of chronic liver diseases. Rinsho Byori 1992, 40:673-678.
41. Young KC, Lin PW, Hsiao WC, Chang TT, Chang YC, Wu HL. Variation of hepatitis C virus load, hypervariable region 1 quasispecies and CD81 hepatocyte expression in hepatocellular carcinoma and adjacent non-cancerous liver. J Med Virol 2002, 68:188-196. 10.1002/jmv.10195, 12210407.
42. Park CK, Park TR, Kim YB, Kim HY, Yoo JY, Kim CH, Choo SH, Cho JM. Viral loads and E2/NS1 region sequences of hepatitis C virus in hepatocellular carcinoma and surrounding liver. Korean J Intern Med 1997, 12:28-33.
43. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat G, Hamid MA, Mohamed MK, Fontanet A. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006, 55:1183-1187. 10.1136/gut.2005.078147, 1856273, 16434426.
44. Nagata S. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Lond B Biol Sci 1994, 345:281-287. 10.1098/rstb.1994.0107, 7531345.
45. Ozaslan E, Kiliçarslan A, Simşek H, Tatar G, Kirazli S. Elevated serum soluble Fas levels in the various stages of hepatitis C virus-induced liver disease. J Int Med Res 2003, 31:384-391.
46. Jodo S, Kobayashi S, Nakajima Y, Matsunaga T, Nakayama N, Ogura N, Kayagaki N, Okumura K, Koike T. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 1998, 112:166-171. 10.1046/j.1365-2249.1998.00569.x, 1904963, 9649177.
47. Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol 2000, 278:G354-G366.
48. Shiota G, Oyama K, Noguchi N, Takano Y, Kitaoka S, Kawasaki H. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis. Res Commun Mol Pathol Pharmacol 1998, 101:3-12.
49. El Bassiouny AE, El-Bassiouni NEI, Nosseir MMF, Zoheiry MMK, El-Ahwany EG, Salah F, Omran ZSO, Ibrahim RA. Circulating and Hepatic Fas Expression in HCV-Induced Chronic Liver Disease and Hepatocellular Carcinoma. Medscape J Med 2008, 10:130. 2491664, 18679533.
50. Macías J, Sánchez-Quijano A, Pineda JA, Abad MA, Rubio A, Rosa R, Leal M, Lissen E. Minimal liver injury in chronic hepatitis C virus infection is associated with low levels of soluble TNF-alpha/Fas receptors and acquisition in childhood. Liver 2001, 21:410-414. 10.1034/j.1600-0676.2001.210608.x, 11903886.
51. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004, 6:297-305. 10.1016/j.ccr.2004.08.012, 15380520.
52. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000, 223:241-257. 10.1046/j.1525-1373.2000.22335.x, 10719836.
53. Kakumu S, Okumura A, Ishikawa T, Yano M, Enomoto A, Nishimura H. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 1997, 109:458-463. 10.1046/j.1365-2249.1997.4861382.x, 1904782, 9328122.
54. Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998, 111:269-277. 10.1046/j.1365-2249.1998.00469.x, 1904907, 9486392.
55. Parasole R, Izzo F, Perrone F, Pignata S, Galati MG, Leonardi E, Castiglione F, Orlando R, Castello G, Esposito G, Gallo C, Daniele B. Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin Cancer Res 2001, 7:3504-3509.
56. Izzo F, Curley S, Maio P, Leonardi E, Imparato L, Giglio S, Cremona F, Castello G. Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis C virus liver injury and development of hepatocellular cancer. Surgery 1996, 120:100-105. 10.1016/S0039-6060(96)80247-9, 8693411.
57. Priimägi L, Tefanova V, Tallo T, Schmidt E. The role of serum Th1 and Th2 cytokines in patients with chronic hepatitis B and hepatitis C virus infection. Acta Medica Lituanica 2005, 12:28-31.
58. Sawayama Y, Hayashi J, Kawakami Y, Furusyo N, Ariyama I, Kishihara Y, Ueno K, Kashiwagi S. Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection. Dig Dis Sci 1999, 44:163-169. 10.1023/A:1026674705459, 9952238.
59. Kitaoka S, Shiota G, Kawasaki H. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepatogastroenterology 2003, 53:1569-1574.
60. Morshed SA, Fukuma H, Kimura Y, Watanabe S, Nishioka M. Interferon-gamma, interleukin (IL)-2 and IL-2 receptor expressions in hepatitis C virus-infected liver. Gastroenterol Jpn 1993, 28(Suppl 5):59-66. 10.1007/BF02989208, 8395442.
61. Khabar KS, Al-Zoghaibi F, Al-Ahdal MN, Murayama T, Dhalla M, Mukaida N, Taha M, Al-Sedairy ST, Siddiqui Y, Kessie G, Matsushima K. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J Exp Med 1997, 186:1077-1085. 10.1084/jem.186.7.1077, 2199072, 9314556.
62. Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C, Yu WC, Fan ST. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res 2003, 9(16 Pt 1):5996-6001.
63. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol 2001, 18:257-264.
64. Fan XG, Liu WE, Li CZ, Wang ZC, Luo LX, Tan DM, Hu GL, Zhang Z. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediators Inflamm 1998, 7:295-297. 10.1080/09629359890992, 1781851, 9792341.
65. Zekri AR, El-Din HM, Bahnassy AA, El-Shehabi AM, El-Leethy H, Omar A, Khaled HM. TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4. J Med Virol 2005, 75:412-420. 10.1002/jmv.20293, 15648068.
66. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al. Histopathological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699. 10.1016/0168-8278(95)80226-6, 7560864.